Humana Inc. (HUM) $407.78
Humana has staged a breathtaking 103% recovery in just 90 days, but as the stock knocks on the door of its 52-week high, technical exhaustion is finally starting to show.
52-wk High $415.0
📌 Investment Snapshot
- Price of $407.78 reflects a massive 43.6x P/E multiple that dwarfs historical norms.
- Latest Q1 revenue surged to $39.65B with a robust $9.85 EPS print.
- Technical momentum is overextended with RSI at 75.8 and price near 52-week highs.
- Consensus mean target of $330.08 suggests the market has significantly overshot fundamentals.
⏳ WAIT
Humana is currently trapped between a parabolic vertical move and a looming earnings report on July 29. While the momentum is undeniable, entering at a 97% 52-week position ahead of binary event risk is mathematically unfavorable.
| 📍 Entry Zone | $372.00 or below | 🛑 Stop-Loss | $348.00 |
| 📋 Adjust If | Q2 earnings show Medicare Advantage margins expanding beyond 5%. | ||
The Investment Case — Why Now?
The narrative surrounding Humana has shifted from terminal Medicare Advantage (MA) margin compression to a story of aggressive recovery and operational efficiency. Over the last three months, the stock doubled as management successfully navigated regulatory headwinds and stabilized medical loss ratios (MLR). This pivot restored institutional confidence, evidenced by the massive accumulation from Dodge & Cox and Blackrock.
However, the valuation has now detached from the underlying earnings power of the business. At 43x earnings, you are paying a tech-sector premium for a managed care organization facing 4.55% Treasury yields and persistent regulatory scrutiny. Does the current 103% rally reflect a permanent fundamental shift or just a massive short-covering squeeze?
🤔 Does the current 103% rally reflect a permanent fundamental shift or just a massive short-covering squeeze?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Healthcare Plans |
| Dividend Yield | 0.87% |
| Short Interest | 4.1% |
Open chart on TradingView →
📈 Price Action & Technicals
Dead Cross
Outside VA
Filled Bullish FVG at $398.66 on July 13.
Humana’s price action is currently parabolic, trading significantly above its SMA50 ($341.23) and SMA200 ($256.95). The Golden Cross is firmly established, but the distance from the 200-day moving average suggests a ‘rubber band’ effect that is stretched to its limit.
Technical indicators signal immediate exhaustion as the RSI (75.8) enters the danger zone. While the ADX at 49.9 confirms a powerful trend, the MACD has just printed a bearish crossover below its signal line, warning of a momentum shift.
The Smart Money is anchored much lower, with the Volume Profile Point of Control (POC) sitting at $187.21. Trading at $407 puts the stock well outside the Value Area, indicating that current buyers are paying a significant ‘scarcity premium’ for shares.
Volume has dried up to 68% of the 20-day average, a classic sign of buyer exhaustion near resistance. The recent fill of the $398.66 FVG zone suggests that the immediate liquidity gap has been addressed, leaving the stock vulnerable to a pullback.
Historically, when HUM reaches an RSI above 75 while trading 50% above its Anchored VWAP, a mean-reversion event typically tests the 50-day SMA. Staying on the sidelines is the only disciplined move until the stock digests these gains.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| HUM | Humana Inc. | 43.6x |
| UNH | UnitedHealth Group | 22.4x |
| CVS | CVS Health | 11.2x |
| ELV | Elevance Health | 17.8x |
| SPY | S&P 500 Avg | 21.5x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| 2026-03-31 | $39.65B | $9.85 | +22.4% |
| 2025-12-31 | $32.52B | N/A | +0.4% |
| 2025-09-30 | $32.65B | $1.62 | +0.8% |
| 2025-06-30 | $32.39B | $4.52 | +1.2% |
Humana generated $1.1B in Free Cash Flow last quarter, providing a solid cushion for its 0.87% dividend. Despite the massive stock price appreciation, buybacks remained conservative at $0.1B, suggesting management may also view the current price as rich.
The Q1 2026 revenue jump to $39.65B was a massive outlier compared to the previous three quarters of stagnation. This $7B revenue surge suggests a significant expansion in Medicare Advantage enrollment or a major pricing adjustment that has finally hit the top line. Investors should watch the July 29 report to see if this growth rate is sustainable or a one-time accounting tailwind.
🚀 Growth Drivers — What Moves the Stock
- Medicare Advantage Recovery 🟡 Priced In — Stabilizing medical loss ratios and better-than-expected CMS reimbursement rates are driving margin expansion.
- CenterWell Expansion 🟢 Upside Surprise — Humana’s primary care and home health segment is scaling rapidly, diversifying revenue away from pure insurance.
- Operational Efficiency 🟡 Priced In — Aggressive cost-cutting measures implemented in late 2025 are finally flowing through to the bottom line.
🤔 Can CenterWell’s growth offset the regulatory risks inherent in the Medicare Advantage program?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| Dodge & Cox Inc. | 11,380 |
| Blackrock Inc. | 10,199 |
| Vanguard Capital Management | 7,838 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| RECHTIN JAMES A. | CEO | 2026-05-01 | Purchase | 35,633 |
| MELLET CELESTE | CFO | 2026-05-01 | Purchase | 15,387 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 4.1% | 2.8 |
⚠ Key Risk Factors
~$4.5B impact
-40% downside
Capital outflow
🎯 Guidance & Wall Street View
Management has signaled a focus on margin restoration over pure membership growth for the remainder of 2026.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $502.00 | $330.08 | $195.00 | 24 | Buy |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Wells Fargo | Overweight | $450.00 | 2026-07-13 | Upgrade |
| TD Cowen | Hold | $340.00 | 2026-07-14 | Maintained |
| Mizuho | Outperform | $420.00 | 2026-06-08 | Maintained |
Analysts are deeply divided. While the consensus ‘Buy’ rating remains, the average price target is nearly 20% below the current price, suggesting that analysts haven’t updated their models to reflect the recent vertical move.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- Medicare Advantage margins return to 5%+ faster than expected.
- CenterWell becomes a standalone valuation driver.
📊 Base Case
Humana consolidates between $360 and $410 as it digests the 100% gain.
🐻 Bear Case
- Earnings miss on July 29 triggers a massive ‘sell the news’ event.
- Regulatory crackdown on MA marketing and sales practices.
🎯 Investor Action Plan — By Profile
The risk/reward is poor with RSI at 75.8. Wait for a pullback to the $372 bullish FVG zone before considering a long entry.
Do not chase this vertical move. The technical confluence score of 60 is moderate, but the detachment from the $270 VWAP is a major warning sign.
If you bought the dip at $163, take partial profits. The long-term thesis is intact, but the current valuation is historically extreme.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: Why is Humana stock rising so fast?
A combination of better-than-expected earnings, a short squeeze, and a sector-wide rotation back into healthcare after 2025’s lows.
Q: Is Humana overvalued at $407?
Yes, on a historical basis. Its 43.6x P/E is more than double its 5-year average, suggesting significant speculative froth.
Q: When is the next major catalyst for HUM?
The Q2 earnings report on July 29, 2026, will be the decisive moment for the current rally.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 Want to verify if this analysis still holds?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Managed care stocks are subject to significant regulatory and legislative risks.
All active positions and their real-time performance are tracked on our Investment Log.
#HUM #Humana #HealthcareStocks #MedicareAdvantage #StockMarket #WallStreet #Investing #TechnicalAnalysis